Cyclerion Therapeutics (KRSA) – Investment Analysts’ Recent Ratings Changes

Several brokerages have updated their recommendations and price targets on shares of Cyclerion Therapeutics (NASDAQ: KRSA) in the last few weeks:

• 9/14/2026 – Cyclerion Therapeutics is now covered by TD Cowen. They set a “buy” rating on the stock.
• 9/14/2026 – Cyclerion Therapeutics is now covered by Stifel Nicolaus. They set a “buy” rating and a $43.00 price target on the stock.
• 9/11/2026 – Cyclerion Therapeutics is now covered by UBS Group AG. They set a “buy” rating and a $55.00 price target on the stock.
• 9/10/2026 – Cyclerion Therapeutics was upgraded by UBS Group AG to “strong-buy”.
• 9/9/2026 – Cyclerion Therapeutics was upgraded by Zacks Research to “hold”.

Cyclerion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for serious diseases with substantial unmet medical needs. The company was established in 2019 as a spinout from Ironwood Pharmaceuticals and built its research portfolio around soluble guanylate cyclase (sGC) stimulation, a mechanism involved in regulating blood flow and cellular signaling.

Cyclerion’s development programs included olinciguat, an investigational therapy studied in sickle cell disease and other vascular conditions; praliciguat, an sGC stimulator evaluated for cardiometabolic and renal diseases; and IW-6463, a central nervous system-penetrant sGC stimulator investigated for neurological disorders.